Stephens Consulting LLC Sells 201 Shares of CVS Health Co. (NYSE:CVS)

Stephens Consulting LLC trimmed its position in CVS Health Co. (NYSE:CVS) by 18.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 867 shares of the pharmacy operator’s stock after selling 201 shares during the quarter. Stephens Consulting LLC’s holdings in CVS Health were worth $69,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its stake in CVS Health by 75.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 50,634 shares of the pharmacy operator’s stock worth $3,535,000 after purchasing an additional 21,726 shares during the period. Bank of Nova Scotia grew its stake in CVS Health by 120.3% during the third quarter. Bank of Nova Scotia now owns 247,889 shares of the pharmacy operator’s stock valued at $17,308,000 after acquiring an additional 135,375 shares in the last quarter. Cape Cod Five Cents Savings Bank purchased a new stake in CVS Health in the 3rd quarter worth $223,000. Teza Capital Management LLC bought a new position in shares of CVS Health during the 3rd quarter valued at about $2,825,000. Finally, Rehmann Capital Advisory Group grew its position in shares of CVS Health by 5.4% during the third quarter. Rehmann Capital Advisory Group now owns 21,731 shares of the pharmacy operator’s stock valued at $1,517,000 after purchasing an additional 1,116 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Insider Activity

In other news, Director Edward J. Ludwig bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was bought at an average price of $53.88 per share, with a total value of $53,880.00. Following the completion of the transaction, the director now directly owns 21,630 shares of the company’s stock, valued at approximately $1,165,424.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.24% of the company’s stock.

CVS Health Stock Up 1.2 %

NYSE:CVS traded up $0.70 during mid-day trading on Friday, reaching $59.06. The company’s stock had a trading volume of 14,343,538 shares, compared to its average volume of 11,322,786. The company has a quick ratio of 0.61, a current ratio of 0.81 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $74.14 billion, a PE ratio of 10.38, a price-to-earnings-growth ratio of 0.56 and a beta of 0.53. The stock has a fifty day moving average of $59.56 and a 200-day moving average of $70.13. CVS Health Co. has a 1 year low of $52.77 and a 1 year high of $83.25.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The company had revenue of $88.44 billion for the quarter, compared to analysts’ expectations of $89.33 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.20 EPS. Equities research analysts forecast that CVS Health Co. will post 7.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Leerink Partnrs cut CVS Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. cut their target price on shares of CVS Health from $101.00 to $86.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. TD Cowen downgraded shares of CVS Health from a “buy” rating to a “hold” rating and decreased their price target for the company from $99.00 to $59.00 in a research note on Tuesday, May 7th. Cantor Fitzgerald reissued a “neutral” rating and issued a $58.00 price objective on shares of CVS Health in a research note on Wednesday, June 12th. Finally, Wells Fargo & Company decreased their target price on shares of CVS Health from $76.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 7th. Eleven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $75.05.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.